Answer

No universal pediatric dosage guidelines exist for medical cannabis. The FDA has approved one cannabis-derived prescription drug for children: Epidiolex (cannabidiol). It treats seizures linked to Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in patients age 1 year and older. The FDA label gives weight-based dosing. For THC products, no standard pediatric dose exists. Clinicians do not have a published schedule to follow.

cbd for pediatric cancer supportive care

FDA-approved cannabidiol dosing

Epidiolex dosing starts at 2.5 mg/kg twice daily. After 1 week, the dose rises to 5 mg/kg twice daily. For Lennox-Gastaut and Dravet, the label allows weekly increases of 2.5 mg/kg twice daily to a maximum of 10 mg/kg twice daily. For tuberous sclerosis complex, the label allows weekly increases to a maximum of 12.5 mg/kg twice daily. A clinician adjusts the dose for side effects and liver tests.

states with pediatric medical cannabis programs

THC products

No pediatric THC product has FDA approval. No dosing guideline from a US medical board sets a pediatric THC dose. Published case reports use different products, routes, and doses. They do not form a standard. THC can cause sedation, balance problems, fast heart rate, and breathing problems when combined with other sedatives. Child brain development continues into the 20s. Heavy THC exposure during this period is a concern.

pediatric cannabis for epilepsy in children

Product quality

CBD and THC products sold online are not standardized. Potency labels can be wrong. Products can contain pesticides, heavy metals, and variable THC amounts. FDA has warned about CBD products with inaccurate labels. For a child, a product with unknown potency is a safety risk.

pediatric cannabis for epilepsy in children

Clinical practice

The American Academy of Pediatrics states that no evidence supports medical marijuana for children outside FDA-approved products. The group advises against off-label use. Some clinicians prescribe CBD or THC off label for severe epilepsy or other conditions. These prescriptions use titration, weight-based starting doses, and close monitoring. They are not a public guideline.

Key points